Summary
Global Interstitial Cystitis Drugs Market 2021-2025
Technavio has been monitoring the interstitial cystitis drugs market and it is poised to grow by $ 283.95 mn during 2021-2025, progressing at a CAGR of 5.06% during the forecast period. Our report on the interstitial cystitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of interstitial cystitis and increasing awareness of interstitial cystitis. In addition, the high prevalence of interstitial cystitis is anticipated to boost the growth of the market as well.
The interstitial cystitis drugs market analysis includes the type segment and geographic landscape.
Technavio's interstitial cystitis drugs market is segmented as below:
By Type
Oral therapy
Intravesical therapy
By Geography
North America
Europe
Asia
ROW
This study identifies the increasing grants for research on interstitial cystitisas one of the prime reasons driving the interstitial cystitis drugs market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on interstitial cystitis drugs market covers the following areas:
Interstitial cystitis drugs market sizing
Interstitial cystitis drugs market forecast
Interstitial cystitis drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading interstitial cystitis drugs market vendors that include Astellas Pharma Inc., Bayer AG, Johnson and Johnson Inc., Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the interstitial cystitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/interstitial-cystitis-drugs-market-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
ページTOPに戻る
Table of Contents
Executive Summary
Market overview
Market Landscape
Market ecosystem
Value chain analysis
Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
Market Segmentation by Type
Market segments
Comparison by Type
Oral therapy - Market size and forecast 2020-2025
Intravesical therapy - Market size and forecast 2020-2025
Market opportunity by Type
Customer landscape
Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends
Vendor Landscape
Overview
Vendor landscape
Landscape disruption
Vendor Analysis
Vendors covered
Market positioning of vendors
Astellas Pharma Inc.
Bayer AG
Johnson and Johnson Inc.
Novartis AG
Perrigo Co. Plc
Pfizer Inc.
Seikagaku Corp.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations
Exhibits1: Key Finding 1
Exhibits2: Key Finding 2
Exhibits3: Key Finding 3
Exhibits4: Key Finding 5
Exhibits5: Key Finding 6
Exhibits6: Key Finding 7
Exhibits7: Key Finding 8
Exhibits8: Parent market
Exhibits9: Market characteristics
Exhibits10: Offerings of vendors included in the market definition
Exhibits11: Market segments
Exhibits12: Global - Market size and forecast 2020 - 2025 ($ million)
Exhibits13: Global market: Year-over-year growth 2020 - 2025 (%)
Exhibits14: Five forces analysis 2020 & 2025
Exhibits15: Bargaining power of buyers
Exhibits16: Bargaining power of suppliers
Exhibits17: Threat of new entrants
Exhibits18: Threat of substitutes
Exhibits19: Threat of rivalry
Exhibits20: Market condition - Five forces 2020
Exhibits21: Type - Market share 2020-2025 (%)
Exhibits22: Comparison by Type
Exhibits23: Oral therapy - Market size and forecast 2020-2025 ($ million)
Exhibits24: Oral therapy - Year-over-year growth 2020-2025 (%)
Exhibits25: Intravesical therapy - Market size and forecast 2020-2025 ($ million)
Exhibits26: Intravesical therapy - Year-over-year growth 2020-2025 (%)
Exhibits27: Market opportunity by Type
Exhibits28: Customer landscape
Exhibits29: Market share by geography 2020-2025 (%)
Exhibits30: Geographic comparison
Exhibits31: North America - Market size and forecast 2020-2025 ($ million)
Exhibits32: North America - Year-over-year growth 2020-2025 (%)
Exhibits33: Europe - Market size and forecast 2020-2025 ($ million)
Exhibits34: Europe - Year-over-year growth 2020-2025 (%)
Exhibits35: Asia - Market size and forecast 2020-2025 ($ million)
Exhibits36: Asia - Year-over-year growth 2020-2025 (%)
Exhibits37: ROW - Market size and forecast 2020-2025 ($ million)
Exhibits38: ROW - Year-over-year growth 2020-2025 (%)
Exhibits39: Key leading countries
Exhibits40: Market opportunity by geography ($ million)
Exhibits41: Impact of drivers and challenges
Exhibits42: Vendor landscape
Exhibits43: Landscape disruption
Exhibits44: Industry risks
Exhibits45: Vendors covered
Exhibits46: Market positioning of vendors
Exhibits47: Astellas Pharma Inc. - Overview
Exhibits48: Astellas Pharma Inc. - Product and service
Exhibits49: Astellas Pharma Inc. - Key offerings
Exhibits50: Astellas Pharma Inc. - Key customers
Exhibits51: Astellas Pharma Inc. - Segment focus
Exhibits52: Bayer AG - Overview
Exhibits53: Bayer AG - Business segments
Exhibits54: Bayer AG - Key offerings
Exhibits55: Bayer AG - Key customers
Exhibits56: Bayer AG - Segment focus
Exhibits57: Johnson and Johnson Inc. - Overview
Exhibits58: Johnson and Johnson Inc. - Business segments
Exhibits59: Johnson and Johnson Inc. - Key offerings
Exhibits60: Johnson and Johnson Inc. - Key customers
Exhibits61: Johnson and Johnson Inc. - Segment focus
Exhibits62: Novartis AG - Overview
Exhibits63: Novartis AG - Business segments
Exhibits64: Novartis AG - Key offerings
Exhibits65: Novartis AG - Key customers
Exhibits66: Novartis AG - Segment focus
Exhibits67: Perrigo Co. Plc - Overview
Exhibits68: Perrigo Co. Plc - Business segments
Exhibits69: Perrigo Co. Plc - Key offerings
Exhibits70: Perrigo Co. Plc - Key customers
Exhibits71: Perrigo Co. Plc - Segment focus
Exhibits72: Pfizer Inc. - Overview
Exhibits73: Pfizer Inc. - Business segments
Exhibits74: Pfizer Inc. - Key offerings
Exhibits75: Pfizer Inc. - Key customers
Exhibits76: Pfizer Inc. - Segment focus
Exhibits77: Seikagaku Corp. - Overview
Exhibits78: Seikagaku Corp. - Business segments
Exhibits79: Seikagaku Corp. - Key offerings
Exhibits80: Seikagaku Corp. - Key customers
Exhibits81: Seikagaku Corp. - Segment focus
Exhibits82: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits83: Sun Pharmaceutical Industries Ltd. - Product and service
Exhibits84: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits85: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibits86: Sun Pharmaceutical Industries Ltd. - Segment focus
Exhibits87: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits88: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits89: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits90: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibits91: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits92: Viatris Inc. - Overview
Exhibits93: Viatris Inc. - Business segments
Exhibits94: Viatris Inc. - Key offerings
Exhibits95: Viatris Inc. - Key customers
Exhibits96: Viatris Inc. - Segment focus
Exhibits97: Currency conversion rates for US$
Exhibits98: Research Methodology
Exhibits99: Validation techniques employed for market sizing
Exhibits100: Information sources
Exhibits101: List of abbreviations
